Who
Reed Vaughn Tuckson
Director
Company insider
Files Form 4 as: Director, Henry Schein; Director, Adverum Biotechnologies; Director, Cti Biopharma; Director, Legacy Lifepoint Health; EVP & Chief of Medical Affairs, UnitedHealth Group.
In numbers
- Trades disclosed
- 102
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $22.5M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 3 Feb 2011
- Last trade
- 6 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 9 Mar 2026 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,577 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,577 at $0.00 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,520 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,450 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,450 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code F | $35K487 at $71.14 | filing |
| 4 Mar 2025filed 6 Mar 2025 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code F | $40K572 at $70.31 | filing |
| 4 Mar 2025filed 6 Mar 2025 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,844 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,520 at $0.00 | filing |
| 4 Mar 2024filed 5 Mar 2024 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code A | —2,604 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | HSIC Henry ScheinHealth Care Distribution | SEC FORM 4 Code F | $38K495 at $76.88 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —120,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —126,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —80,000 | filing |
| 26 Jun 2023filed 26 Jun 2023 | Cti Biopharmaoption or derivative | SEC FORM 4 Code D | —80,000 | filing |
News
UnitedHealth Group (NYSE:UNH) Given New $524.00 Price Target at JPMorgan Chase & Co.UNH · tickerreport.com · 16 Oct 2026UnitedHealth targets 13% to 16% long-term growth as 2026 adjusted EPS guidance moves to at least $20.50 (NYSE:UNH)UNH · seekingalpha.com · 13 Oct 2026UnitedHealth: Huge Earnings Surprise (NYSE:UNH)UNH · seekingalpha.com · 13 Oct 2026
0 headlines in the last 90 days name Reed Vaughn Tuckson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.